The aim of the study was to investigate the safety and efficacy of apomorphine SL (apo SL) 2 and 3 mg, using a dose-optimisation regime in 110 Asian men with erectile dysfunction (ED) during a 10-week open-label study. Based on daily diaries kept by each patient, 63% showed an improvement in their sexual life. Patient responses to the International Index for Erection Function 15 questionnaires showed that there was an improvement in erectile function from baseline score after treatment with apo SL (from 15.9 to 20.4), and intercourse satisfaction (from 7.7 to 9.9), as well as slight improvements in orgasmic function (from 6.8 to 7.5) and total satisfaction (from 41.9 to 50.8). There was no marked improvement seen in sexual desire. In conclusion, apo SL is safe and efficacious in the treatment of ED in this patient population, irrespective of underlying diseases and concomitant medications.
Introduction
The erectile dysfunction (ED) survey in Thailand was the first full study of the prevalence rate of ED to be carried out in Thailand and it demonstrated that over 3 million males suffered from ED in this country. 1 In a nationwide representative sample of 1250 Thai men aged between 40 and 70 y, the estimation of overall prevalence of ED among the respondents living in urban areas was 37.5%. 2 Of these, approximately 19.1% of males had mild dysfunction, while about 13.7 and 4.7% of the sample population had moderate and severe dysfunction, respectively. When the effects of socioeconomic factors of ED were considered in the survey, it was seen that education played an important part in the prevention of serious ED. The survey showed that only 0.9% of university graduates suffered from ED compared to 9.0% of men who had not continued onto further education from school. 2 Education was seen to play a major role in the perception, awareness and preparation for any sexual dysfunction problems that may occur in later life.
In a recent European study of 507 patients with ED, the safety and tolerability of 2-4 mg apo SL was examined in a forced-dose-escalation regimen. 3 In this study, adverse events were not treatment limiting and the risk/benefit ratio supported apo SL as a safe and effective therapy for managing ED. In an 8-week, double-blind clinical trial of 569 patients in the US, apo SL 2-6 mg was investigated. 4 In this study, all the apo SL dosage groups showed a higher percentage of patients compared with patients in the placebo group achieving and maintaining an erection firm enough for intercourse (ranging from 48 to 53% in the apo SL groups versus 35% for placebo, Pr0.001) and a significantly higher percentage of attempts resulting in intercourse (45-51% in the apo SL groups versus 33% for placebo, Pr0.001). Nausea was the most common side effect, but it was dose related and decreased greatly after 4 weeks at all doses.
In order to further assess the efficacy and tolerability of apo SL, an open label study was recently completed to determine dose optimisation in 110 Asian men in Thailand. The study population included men with coexisting diseases, including hypertension, diabetes and cardiovascular disease, as well as those taking concomitant medication including nitrates.
Materials and methods

Patients
The study was carried out in 110 adult Asian males (mean age 56 y; average weight 69 kg; average height 166 cm) with a history of at least 6 weeks ED prior to the start of the study. Figure 1 shows the percentage of patients taking concomitant medications including hyperlipidaemics (o10%), cardiovascular drugs including nitrates (o10%), antihypertensives (B35%) and peripheral vascular agents (o5%). Approximately 58% of the patients were taking more than one additional medication. Patients with coexisting organic disease included less than 30% with hypertension, approximately 25% of patients with benign prostatic hyperplasia, less than 30% with diabetes, less than 5% with cardiovascular disease and less than 35% with hyperlipidaemia ( Figure 2 ). Approximately 10% of the patients enrolled were smokers. Of the entire patient population, 40% had mild ED, 39% moderate ED and 21% suffered from severe ED.
Study protocol
The study protocol consisted of a 2-week washout period followed by 8 weeks of sublingual apo SL.
Patients had a physical examination during this time. This was followed by a 2-week optimisation period when patients took two treatments of 2 mg apo SL followed by at least two 3 mg doses. For the remaining 6 weeks of the study, patients were allowed to choose their optimal dose. Patients were asked to keep a daily diary and patient outcome was assessed using the International Index for Erection Function 15 (IIEF-15) at the second and fourth visit. 5 The IIEF-15 is a self-administered, 15-item questionnaire that covers the following five parameters: ED; orgasmic function; sexual desire; satisfaction with relations and overall satisfaction.
Results
Of the 110 patients enrolled, 39 did not complete the study because of failure at screening (n ¼ 4), withdrawal from study (n ¼ 7) and failure to meet the protocol (as they did not attend the first meeting, n ¼ 28). Four patients chose 2 mg apo SL and 67 patients chose 3 mg apo SL. Of the 71 patients who completed the study, 45 patients had a good response. There were no changes in liver profile or other chemistry and testosterone levels remained normal in all cases. Reasons for discontinuation included lack of efficacy (n ¼ 2), adverse events (n ¼ 2), partner's request (n ¼ 1) and noncompliance (n ¼ 5).
Based on the daily diaries, 63% of patients showed an improvement in their sexual life. There was an improvement in the baseline scores of the IIEF-15 scale for all five parameters studied. Scores in erectile function increased from 15.9 before apo SL treatment to 20.4 after treatment, intercourse satisfaction scores increased from 7.7 before treatment to 9.9 after treatment. A slight improvement in orgasmic function was seen with an increase in IIEF-15 score from 6.8 to 7.5 and in total satisfaction from 41.9 to 50.8, before and after treatment, respectively. There was little improvement in sexual desire reported using the IIEF-15 score with scores of 5.4 and 6.4 before and after treatment, respectively (Table 1) . Patients took two doses of apo SL 2 mg followed by at least two doses of apo SL 3 mg in the 2-week dose-optimisation period. Patients then chose 2 or 3 mg apo SL for the remaining 6 weeks of the study.
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In this patient population, adverse events were mild, with five patients experiencing nausea. These patients were initially prescribed antiemetics, but symptoms improved in time without any further medication. Other side effects also included dizziness (n ¼ 1), palpitations (n ¼ 2) and tongue oedema (n ¼ 1). No vasovagal syncope was reported with this dosing regimen.
Discussion and conclusion
In a US dose-optimisation study of apo SL, all domains of the IIEF-15 were significantly improved by apo SL, with the exception of libido, indicating that apo SL is not an aphrodisiac. 4 In this US study, the dose-optimisation regimen successfully decreased the occurrence of adverse events, with nausea being the most common. Among the 569 patients studied, the occurrence of nausea was reduced from 49% in the 6 mg group to 17% in the dose-optimisation group after a 2 or 4 mg dose. Only 2% of the patients reported the nausea to be severe. In this open label study of 110 patients in Thailand, it was demonstrated that apo SL was safe and efficacious in the treatment of ED in Asian men, particularly when utilised with a dose-optimisation paradigm. A marked improvement in IIEF-15 scores was seen in the parameters of ED, and intercourse satisfaction, as well as a slight improvement in orgasmic function and overall satisfaction, irrespective of the wide range of underlying concomitant diseases and associated medications being used by the patients in this study. Patients taking cardiovascular drugs such as nitrates responded well with minimal side effects. Some studies, including a double-blind crossover comparison study of 3 mg apo SL with placebo and 4 mg apo SL, showed that transient vasovagal syncope can be an adverse event of apo SL. 6, 7 However, it is very rare in patients when a dose-optimisation programme has been followed and no patients suffered from syncope in our study.
The socioeconomic factors of ED outlined by the Thai survey study showed that patient education plays a major role in the understanding of ED and patient knowledge affects the outcome of the treatment regimen. 2 Proper instruction concerning dose optimisation is therefore necessary for individuals to achieve good results. It is also necessary for the patient to observe good practice for self-administration, because apo SL is more effective when used sublingually. It is therefore important to stress to the patient that sublingual means to place the tablet under the tongue to dissolve slowly without swallowing it. We recommend that the patients follow the 4S rule to better remember the importance of drug administration. The 4S's stand for: sublingual administration, sequential dosing, leading to stimulation (erection) and then sexual intercourse. The window of opportunity to maximise the efficacy of medication in ED is small, and therefore it is vital that counselling and consultation are included in the first meeting of the patient.
